Tyra Biosciences financials
$21.98+2.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$49.0M | -$42.0M | -$36.5M | -$32.9M | -$31.5M | -$31.9M | -$29.7M | -$28.6M | -$23.5M | -$22.3M | -$25.6M | -$24.0M |
| Net income | -$45.6M | -$39.3M | -$33.5M | -$29.9M | -$28.1M | -$28.1M | -$26.9M | -$22.1M | -$18.7M | -$18.2M | -$22.8M | -$21.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.69 | $-0.64 | $-0.56 | $-0.50 | $-0.47 | $-0.47 | $-0.46 | $-0.41 | $-0.32 | $-0.35 | $-0.53 | $-0.49 |
| EBITDA | -$48.9M | -$41.9M | -$36.4M | -$32.8M | -$31.3M | -$31.7M | -$29.6M | -$28.5M | -$23.4M | -$22.2M | -$25.5M | -$23.9M |
| Operating cash flow | -$31.1M | -$32.6M | -$23.6M | -$22.4M | -$23.7M | -$25.5M | -$19.6M | -$17.9M | -$10.3M | -$22.0M | -$13.5M | -$17.1M |
| Free cash flow | -$31.1M | -$32.7M | -$23.7M | -$22.4M | -$23.7M | -$25.5M | -$19.6M | -$17.9M | -$10.7M | -$22.2M | -$14.1M | -$17.2M |
| Diluted shares | 66.0M | 61.7M | 59.9M | 59.7M | 59.6M | 59.3M | 59.1M | 58.9M | 58.7M | 52.2M | 43.0M | 42.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.8M | $85.0M | $77.4M | $62.0M | $98.5M | $100.7M |
| Short-term investments | $280.1M | $298.5M | $178.6M | $213.0M | $197.8M | $218.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $383.4M | $412.0M | $282.6M | $301.9M | $321.5M | $343.5M |
| Total liabilities | $29.7M | $24.5M | $23.4M | $21.3M | $19.4M | $19.9M |
| Shareholders' equity | $353.7M | $387.6M | $259.2M | $280.5M | $302.1M | $323.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology